A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk

Gemma Tell-Marti1,2, Joan Anton Puig-Butille3,2, Miriam Potrony1

  • 1Dermatology Department, Melanoma Unit, Hospital Clinic & IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Spain.

Insights

A common variant in the MC1R gene (p.V92M) increases the risk for late-onset Alzheimer's disease (LOAD), particularly in individuals without APOE gene risk factors. This finding suggests MC1R as a potential new target for LOAD research.

Area of Science:

  • Neurogenetics
  • Alzheimer's Disease Research
  • Human Genetics

Background:

  • The genetic underpinnings of late-onset Alzheimer's disease (LOAD) remain incompletely understood, with known risk genes explaining only a portion of the genetic variance.
  • APOE gene variants are significant contributors to LOAD risk, but a substantial portion of genetic susceptibility is yet to be identified.

Purpose of the Study:

  • To investigate the potential role of the Melanocortin 1 Receptor (MC1R) gene in the genetic etiology of LOAD.
  • To identify novel genetic factors contributing to Alzheimer's disease susceptibility.

Main Methods:

  • Sequencing of the MC1R gene in a cohort of 525 Spanish LOAD patients and 160 healthy controls.
  • Statistical analysis to assess the association between MC1R variants and LOAD risk, including stratification by APOE genotype and cerebrospinal fluid (CSF) AD profile.

Main Results:

  • A common MC1R variant, p.V92M (rs2228479), was found to be significantly associated with an increased risk of developing LOAD (OR: 1.99).
  • The association was more pronounced in LOAD patients without APOE risk factors and those with a typical AD CSF profile.
  • No association was observed between the MC1R p.V92M variant and the age of onset for Alzheimer's disease.

Conclusions:

  • The MC1R gene, specifically the p.V92M variant, represents a potential novel genetic risk factor for late-onset Alzheimer's disease.
  • Further research is warranted to elucidate the functional mechanisms of MC1R in brain cells and its pathways in the context of AD pathogenesis.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
77
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K